Remove Books Remove Cell Biology Remove Licensing
article thumbnail

First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

The Pharma Data

AstraZeneca will book all sales revenue and will pay Innate low double-digit to mid-teen percentage royalties on net sales worldwide except in Europe where Innate Pharma will receive 50% share of the profits and losses in the territory. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Progress in biology is arguably moving faster today than at any point in the course of human history. Engineered biology has profound potential to change how we live, but the field has become broad, bloated, nebulous. Nature Reviews Molecular Cell Biology (2009).

DNA 90
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Last edit: 13 September 2023 Progress in biology is arguably moving faster today than at any point in the course of human history. Engineered biology has profound potential to change how we live, but the field has become broad, bloated, nebulous. & Weiss R.

DNA 52
article thumbnail

Codon Digest: GPT-4 Controls a Robot

Codon

epidermidis , can actually trigger tumor-specific T cells. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study. Nature Cell Biology.